Studies revealed that regulation of the Ras-Raf-MAPK pathway is abrogated in the majority of melanoma tumors as a result of activating NRAS or BRAF mutations, which are mutually exclusive and present in up to 90% of cutaneous melanomas [2]. This evidence concerns the gene BRAF and cutaneous melanoma.